Adverts

Open Access Articles- Top Results for Mitozolomide

Mitozolomide

</th></tr>
Mitozolomide
File:Mitozolomide.svg
Systematic (IUPAC) name
3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Clinical data
Identifiers
85622-95-3 7pxY
None
PubChem CID 71766
ChemSpider 64805 7pxN
UNII E3U7286V3W 7pxN
ChEMBL CHEMBL435951 7pxN
Chemical data
Formula C7H7ClN6O2
242.622 g/mol
 14pxN (what is this?)  (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References

  1. ^ Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther 7 (2): 233–9. PMID 10770631. doi:10.1038/sj.cgt.7700120. 
  2. ^ Newlands ES, Blackledge GR, Slack JA et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer 65 (2): 287–91. PMC 1977719. PMID 1739631. doi:10.1038/bjc.1992.57. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.